Keyword: Galera Therapeutics

Galera will use the proceeds to start a phase 3 study of GC4419, which seems to prevent severe oral mucositis in patients with head and neck cancers.

Galera's synthetic enzyme GC4419, appears to stave off severe oral mucositis, a side effect of cancer treatment.